Pulmatrix announces positive final results from phase 1/1b clinical trial of pulmazole
Pulmatrix announced the results of the completed first-in-human study of Pulmazole (PUR1900) — an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for treatment of allergic bronchopulmonary aspergillosis in patients with asthma. November 21, 2018